[1] |
Nahal SK, Selmi C, Gershwin ME. Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythemayosus[J]. J Autoimmun, 2018, 93: 16-23.
|
[2] |
Tavakolpour S, Rahimzadeh G. New Insights into the Management of Patients with Autoimmune Diseases or Inflammatory Disorders During Pregnancy[J]. Scand J Immunol, 2016, 84(3): 146-149.
|
[3] |
Erbet R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases:Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult.The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35(41): 2873-2926.
|
[4] |
中国医师协会心血管外科分会大血管外科专业委员会,主动脉夹层诊断与治疗规范中国专家共识[J]. 中国胸心血管外科杂志,2017, 33(11): 641-654.
|
[5] |
中国系统性红斑狼疮研究协作组专家组,国家风湿病数据中心. 中国系统性红斑狼疮患者围产期管理建议[J]. 中华医学杂志,2015, 95(14): 1056-1060.
|
[6] |
Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016, 75(5): 795-810.
|
[7] |
Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids[J]. Rheumatology (Oxford), 2016, 55(9): 1693-1697.
|
[8] |
Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women′s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome[J]. Ann Rheum Dis, 2017, 76(3): 476-485.
|
[9] |
Ruiz-Irastorza G, Khamashta MA.Evaluation of systemic lupus erythematosus activity during pregnancy[J]. Lupus, 2004, 13(9): 679-682
|
[10] |
Laura A, Maria CG, Melissa F, et al. Disease activity assessment of rheumatic disease during pregnancy:a comprehensive review of in clinical studies[J]. Autoimmun Rev, 2019, 18(2): 164-176.
|